Mehul R. Dalal

机构：Takeda (United States) · ORCID：0000-0002-7417-0817

发表论文 113 篇 · 总被引 2781 次 · h-index 20

代表论文

• Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom (2018 · British Journal of Haematology · 被引 55)
• Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study (2020 · European Journal of Cancer · 被引 31)
• Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice (2018 · Diabetes Spectrum · 被引 27)
• Clinical Impact of Transformation to Acute Myeloid Leukemia in Patients With Higher-Risk Myelodysplastic Syndromes (2022 · Future Oncology · 被引 24)
• Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries (2021 · Cancers · 被引 16)
• The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review (2020 · Expert Review of Hematology · 被引 16)